NCT05933668尚未招募1 期
Phase I Clinical Study of YK0901 Injection for the Treatment of Advanced Solid Tumors With HLA-A * 11:01 Positive and KRAS G12V Mutation
Peking University1 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2023年7月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Treatment related AEs
研究概览
简要总结
This study is a single center, open, single arm, dose increasing early clinical study. The purpose of this study is to evaluate the safety and efficacy of YK0901 immunotherapy in the treatment of patients with advanced solid tumor whose tumor antigen KRAS G12V expression is positive (HLA-A * 11:01).
详细描述
KRAS mutations exist in various cancers, especially pancreatic, lung and colorectal cancer. G12V is one of the most common mutation types for KRAS. It's challenging to chemically acquire the targeted drug for this mutation. Recent studies reported that this mutation peptides can form a neoepitope for T cell recognition.Our study aims to evaluate the safety and tolerability of YK0901 TCR-T cell for KRAS G12V positive advanced solid tumors.In this trial, 11 subjects with KRAS G12V mutations and matching HLA-A*11:01 subtypes are recruited for autologous TCR-T therapy.Within 1-7days after pretreatment, subjects will receive a single TCR-T infusion with an infusion dose of about 1×108～5×1010.Once every 12 hours within 24 hours after TCR-T cell infusion, recombinant human interleukin-2 will be injected intravenously for 14 days .
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Age ≥18 years and ≤75 years. 2.Failure on or intolerance to systemic therapy for unresectable advanced cancer.
- •3.Patients must have at least one measurable lesion defined by RECIST 1.
- •4.Genotype and tumor antigen screening must meet the following two criteria: 1) HLA-A * 11:01 positive; 2) KRAS G12V positive 5.ECOG score 0-1 and expected survival time ≥3 months 6.Patients must meet the following criteria at screening and before preconditioning (baseline). If any laboratory test result is abnormal referring to the following criteria, it is acceptable to test one more time within 1week. If the test result is still abnormal, the patient is screen failed:
- •Hematology (no intensive blood transfusion (≥2 times within 1week), platelet transfusion or cell growth factor (except for recombinant erythropoietin) performed within 7days before the test): neutrophils (NE) ≥1.5×109 per liter, lymphocytes (LY) ≥0.5×109per liter (except for before preconditioning), platelets (PLT) ≥75×109per liter and hemoglobin (Hb) ≥8.0 g/dL.
- •Blood chemistry: creatinine clearance ≥mL/min, alanine aminotransferase (ALT) ≤2.5×ULN, aspartate aminotransferase (AST) ≤2.5×ULN, total bilirubin (TB) ≤2×ULN, serum lipase and amylase <1.5 ULN, alkaline phosphatase (ALP) ≤2.5 ULN; for patients with bone or hepatic metastasis, AST, ALT and ALP <5ULN.
- •Prothrombin time ≤ULN+4 seconds. 7.Women of childbearing potential must have negative serum pregnancy test result at screening and before preconditioning and agree to use an effective and reliable contraceptive method for at least 1 year after the last study treatment. Te acceptable methods include bilateral tubal ligation/bilateral salpingectomy or bilateral tubal occlusion; any approved oral, injection or implantation of hormone; or barrier contraceptive method: condoms containing spermicidal foam/gel/film/paste /suppositories or occlusive cap (diaphragm or cervical/fornix cap).
- •8.Voluntarily willing to participate in the study and sign the written informed consent.
- •9.No systemic anti-tumor therapy received within 2 weeks prior to peripheral blood mononuclear cell (PBMC) collection.
- •10.Blood oxygen saturation (finger oxygen detection)≥ 95% in a calm and non oxygenated state.
排除标准
- •Pregnant or lactating women.
- •HIV, treponema pallidum or HCV serology is positive.
- •Patients with any uncontrolled active infection, including, but not limited to, active tuberculosis or HBV infection (HBsAg positive or HBV DNA positive).
- •Patients with AEs induced by previous treatment that have not recovered to Common Terminology Criteria for Adverse Events (CTCAE) ≤1, except for alopecia and other tolerable events judged by the investigator or permitted laboratory abnormalities according to the protocol.
- •Patient allergic or intolerant to preconditioning drugs, including, but not limited to, fudarabine and cyclophosphamide or oxaliplatin; allergic to the components of YK0901; penicillin allergy history confrmed by positive skin test; or any severe allergy history-for example, anaphylactic shock.
- •Patients who have a history of organ transplantation or are waiting for organ transplantation.
- •Patients who have undergone major surgery or severe trauma within 4weeks before apheresis .
- •Patients with other serious diseases that may restrict them from participating in this study, such as poorly controlled diabetes (glycosylated hemoglobin HbA1c >8% undertreatment), poorly controlled hypertension judged by the investigator (blood pressure >160mmHg/100mmHg), severe cardiac insufficiency (left ventricular ejection fraction <50%), myocardial infarction or unstable arrhythmia or unstable angina pectoris, pulmonary embolism, chronic obstructive pulmonary disease, interstitial lung disease or clinically significant lung function test abnormalities in the past 6months.
- •Before apheresis and preconditioning, patients who have the following conditions, including, but not limited to: new-onset arrhythmia that cannot be controlled by medications; hypotension that requires the use of vasopressors; or bacterial, fungal or viral infections that require intravenous antibiotic, antiviral or antifungal treatment, and the investigator judged that they are not suitable to continue the experiment. Patients who use antibiotics to prevent infection can continue the study upon the judgment of the investigator
- •Patients who are expected to continue using immunosuppressive therapy during the trial (excluding physiological replacement therapy with glucocorticoids, such as prednisone<10mg/d or equivalent doses)
- •Patients with central nervous metastases.
- •Patients who have participated in other intervention clinical trials within 2 weeks.
- •Patients with adverse drug addiction or a history of drug abuse.
- •Patient with other malignant tumors within the past 2 years or at the present, except for cervical cancer in situ and basal cell carcinoma of the skin.
- •Patients who are unable or unwilling to comply with the clinical protocol, by the investigator's judgment.
结局指标
主要结局
Treatment related AEs
时间窗: 2 years
Dose-limiting toxicity (DLT)
时间窗: 2 years
次要结局
- Antitumor efficacy-Objective response rate (ORR)(2 years)
- Antitumor efficacy-Duration of response (DOR)(2 years)
- Antitumor efficacy-Progression-free survival (PFS)(2 years)
- Antitumor efficacy-Overall survival (OS)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Safety,Tolerability, Pharmacokinetic,Pharmacodynamics and Efficacy of KY100001 in Patients With Advanced Solid TumorsAdvanced Solid TumorNCT04906473Kunming Pharmaceuticals, Inc.109
已完成
1 期
A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04357756Eucure (Beijing) Biopharma Co., Ltd29
招募中
2 期
YN001-004 in Patients With Coronary Atherosclerosis in AustraliaCoronary Atherosclerotic DiseaseCoronary Artery DiseaseNCT06700720Beijing Inno Medicine Co., Ltd.24
终止
1 期
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After SurgeryColorectal NeoplasmsNCT00041691Gilead Sciences30
尚未招募
1 期
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaAnti-CD19 STAR T-cell TherapyFailure ≥3 Lines of TherapiesAutoimmune Hemolytic AnemiaNCT06770504Institute of Hematology & Blood Diseases Hospital, China7